Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc.（RLMD）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
rlmd · 股价预测 · 8 位分析师（近3月）· FMP · 更新于 2026年6月9日
分析师评级与共识
基于过去 3 个月内 8 位华尔街分析师
Buy
8 位分析师
共识
评级分布
12 个月目标价
High
$10.00
Consensus
$9.00
+57.3% upside
Low
$8.00
Median: $9 · Last Close: $5.72
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$9.00
57.3% upside
High Target
$10
74.8%
Low Target
$8
39.9%
Current Price
$5.72
as of today
Based on analyst price targets, the RLMD stock price prediction for the next 12 months ranges from $8 to $10. The consensus RLMD price forecast of $9.00 implies 57.3% upside from the current price of $5.72.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $5.43 | ↓ 5.00% |
1-day model range: $5.39–$5.47. Peak: $5.47 (-5.00%).
长期股价预测
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RLMD · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-20 | Mizuho | Maintains | Outperform→Outperform |
| 2026-01-23 | Leerink Partners | Upgrade ↑ | Market Perform→Outperform |
| 2025-11-19 | Mizuho | Upgrade ↑ | Neutral→Outperform |
| 2024-12-05 | Mizuho | Downgrade ↓ | Outperform→Neutral |
| 2024-12-04 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2024-06-05 | Goldman Sachs | Downgrade ↓ | Neutral→Sell |
| 2023-06-15 | Mizuho | Maintains | Buy→Buy |
| 2023-01-23 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-10-14 | Goldman Sachs | Downgrade ↓ | Buy→Neutral |
| 2022-10-14 | Guggenheim | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on Relmada Therapeutics, Inc. (RLMD) stock. Of the recent 25 rating actions, 2 were upgrades and 7 were downgrades. 8 analysts currently cover RLMD.
分析师推荐趋势
RLMD analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$10M
↓ 47.4% YoY
Revenue Next Year
$32M
↑ 224.5% YoY
EPS This Year
$-0.80
EPS Next Year
$-0.96
↑ 19.7% YoY
EPS ForecastReported vs Estimated
Analysts forecast RLMD EPS of $-0.80 for the current fiscal year, based on estimates from 2 analysts. The RLMD revenue forecast is $10M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
RLMD 股价预测由两类独立数据源支撑：来自 8 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。RLMD 的共识目标价为 $9.00（+57.3% 上行空间），分析师共识为 Buy。
RLMD 的短期预测（明日）为 $5.43（-5.00%）。
Relmada Therapeutics, Inc. 在 NASDAQ 上市，代码 RLMD。RLMD 在 2027 年的整体展望偏积极，在覆盖分析师中约 63% 对应 Buy 共识。
常见问题
RLMD 预测 · 8 个问题根据 8 位华尔街分析师，RLMD 的 12 个月平均目标价为 $9.00，最高 $10.00、最低 $8.00。若有图表，中位目标价可在上方查看。相对当前价 $5.72，隐含约 +57.3% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.